- Home
- BMRN vs HOLX Comparison
BMRN vs HOLX Comparison
Compare BMRN & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- HOLX
- Stock Information
- Founded
- BMRN 1996
- HOLX 1985
- Country
- BMRN United States
- HOLX United States
- Employees
- BMRN N/A
- HOLX N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- HOLX Medical Electronics
- Sector
- BMRN Health Care
- HOLX Health Care
- Exchange
- BMRN Nasdaq
- HOLX Nasdaq
- Market Cap
- BMRN 13.7B
- HOLX 16.3B
- IPO Year
- BMRN 1999
- HOLX 1990
- Fundamental
- Price
- BMRN $59.17
- HOLX $57.56
- Analyst Decision
- BMRN Buy
- HOLX Buy
- Analyst Count
- BMRN 22
- HOLX 14
- Target Price
- BMRN $94.00
- HOLX $84.17
- AVG Volume (30 Days)
- BMRN 2.0M
- HOLX 3.7M
- Earning Date
- BMRN 05-01-2025
- HOLX 05-01-2025
- Dividend Yield
- BMRN N/A
- HOLX N/A
- EPS Growth
- BMRN 153.71
- HOLX 50.83
- EPS
- BMRN 2.21
- HOLX 3.16
- Revenue
- BMRN $2,853,915,000.00
- HOLX $4,039,000,000.00
- Revenue This Year
- BMRN $12.23
- HOLX $3.37
- Revenue Next Year
- BMRN $9.93
- HOLX $5.40
- P/E Ratio
- BMRN $26.81
- HOLX $18.24
- Revenue Growth
- BMRN 17.97
- HOLX 1.76
- 52 Week Low
- BMRN $52.93
- HOLX $56.27
- 52 Week High
- BMRN $94.85
- HOLX $84.67
- Technical
- Relative Strength Index (RSI)
- BMRN 37.64
- HOLX 39.33
- Support Level
- BMRN $52.93
- HOLX $56.27
- Resistance Level
- BMRN $60.93
- HOLX $59.02
- Average True Range (ATR)
- BMRN 3.18
- HOLX 2.18
- MACD
- BMRN -0.53
- HOLX -0.19
- Stochastic Oscillator
- BMRN 34.01
- HOLX 23.49
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.